This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lee HJ, Thompson JE, Wang ES, Wetzler M . Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011; 117: 1583–1594.
Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110: 2309–2315.
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141.
Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005; 11: 4941–4947.
Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551.
Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Gehrke B, Petershofen EK et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia 2003; 17: 1700–1706.
Merante S, Colombo AA, Calatroni S, Rocca B, Boni M, Bernasconi P et al. Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. Bone Marrow Transplant 2009; 44: 263–264.
Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R . Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 2009; 33: 174–177.
Castillo E, Al-Rajabi R, Pandya DM, Varadarajan P, Kelly KR, Swords R et al. A pilot study of the combination of nilotinib and hyper-CVAD for Philadelphia chromosome positive acute lymphocytic leukemia and lymphoid blast crisis chronic myelogenous leukemia. Blood 2010; 116: 885–886, (abstract 2144).
US National Institutes of Health. Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (NCT00844298), Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00844298?term=nilotinib+acute+lymphoblastic+leukemia&rank=2. Published 13 February 2009. Updated 2012 (accessed) 7 June 2012.
U.S. National Institutes of Health. Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALLPhi) (NCT00905398), Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00905398?term=nilotinib+acute+lymphoblastic+leukemia&rank=4. Published 2009. Updated 2009 (accessed) 7 June 2012.
US National Institutes of Health. Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT01528085), Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT01528085?term=nilotinib+acute+lymphoblastic+leukemia&rank=1. Published 3 February 2012. Updated 2012 (accessed) 7 June 2012.
Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N . Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 2011; 25: 1314–1323.
Feldhahn N, Arutyunyan A, Stoddart S, Zhang B, Schmidhuber S, Yi SJ et al. Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. Oncoimmunology 2012; 1: 618–629.
Acknowledgements
Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. The authors thank Erinn Goldman, PhD, Cornel Phillip, PhD and Karen Miller-Moslin, PhD, for medical editorial assistance with this paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
OGO, RAL, HMK, PDLeC, MB, AH, DWK and FJG acted as a consultant for, and received research funding from Novartis, XF and SN are employees of Novartis Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Ottmann, O., Larson, R., Kantarjian, H. et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia. Leukemia 27, 1411–1413 (2013). https://doi.org/10.1038/leu.2012.324
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.324
This article is cited by
-
Current Approaches to Philadelphia Chromosome–Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant
Current Oncology Reports (2021)
-
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
Annals of Hematology (2021)
-
Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up
Annals of Hematology (2019)
-
Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Current Treatment Options in Oncology (2017)